Number of participants: 2
Coordinator: Scanomed Ltd.
Partner: BBS Nanotechnology Ltd.
Total Grant Amount: 326 801 971 HUF
Funding rate: 63,24 %
End Date: 31/12/2018
Content of the project:
The project is directly related to drug research and medical diagnostics. During the development, ScanoMed Kft. established an expert system in which imaging data (SPECT/CT, PET/CT, MRI) and other clinical data (physical parameters, laboratory tests, genetic analyzes, etc.) appear in a standard framework.
This framework provides an opportunity for more detailed assay and statistical analysis of a particular patient group, for a more detailed description of the disease by examining clinical relationships. In addition, a software environment has been created to enable special filtering and retrieval of medical imaging data and can be used to monitor patient doses, facilitate patient care logistics and facilitate clinical quality assurance.
BBS Nanotechnology Ltd., as a consortium partner, has determined the optimal composition of the biopolymer molecules and the most suitable method of synthesis for the basic structure of nanoparticles suitable for preclinical testing of angiogenesis-neoangiogenesis at molecular level, and selected the two targeting molecules that are used together in particle formation to enhance the specificity of imaging. The prototype thus created is suitable for preclinical studies of angiogenesis-neoangiogenesis at the molecular level, helping to better understand the process of angiogenesis and to follow its changes.
The development of the molecular imaging diagnostic service supported by the multiparametric expert system was performed by ScanoMed Ltd. as a consortium leader.
The development of a narrow-size, biopolymer-based, targeted nanoparticle containing radioactive isotope-binding chelator molecules was performed by BBS Nanotechnology Ltd.